Clinical trial NCT04315467: Intraoperative Imaging of Pulmonary Nodules by SGM-101
Official title: Intraoperative Molecular Imaging Of Pulmonary Nodules By SGM-101, A Fluorochrome-Labeled Anti-Carcino-Embryonic Antigen (CEA) Monoclonal Antibody
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Lung Cancer
Lung Nodule
Non Small Cell Lung Cancer
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2020-03-19
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The primary objectives of this study are to assess the sensitivity and specificity of SGM-101 in detecting non-small cell lung carcinomas during surgery when excited by an near-infrared light source utilizing intraoperative imaging.

Detailed description: Potential subjects will be seen in a General Thoracic Surgery clinic. If potential subjects have a lung nodule that is suspicious for non-small cell lung cancer, they will be a candidate for the operation and the study. There will be no randomization or control group and only subjects previously scheduled to undergo surgery will be eligible to participate. The investigators anticipate a 24-month period will be necessary to reach the accrual goal of 20 subjects.

After obtaining informed consent, subjects who are confirmed as eligible will receive a one-time dose of 5 to 10 mg of SGM-101, up to 5 days prior to the planned operation. As a prophylactic measure, the Principal Investigator may recommend giving 25 mg of IV Benadryl to the subject prior to the infusion of SGM-101 to ensure the possibility of an allergic reaction is absolutely minimized. The goal of surgery in subjects is to remove the nodule and lymph nodes in concern. During surgery, the investigators will take images with an intra-operative camera system. Imaging will take place prior to surgical resection to record the localization of tumors, and post-resection to document the visualization of any residual tumor.

The duration of surgical procedures to resect thoracic malignancies varies substantially, anywhere from 2-6 hours or more. It is estimated that visualization of the chest and removal of nodules for the purposes of this study will require an additional ten (10) minutes. Due to potential quenching of the fluorophore, visualization time will be limited to 30 minutes.

Cohort 1: The first 10 subjects will be a feasibility trial. The investigators will discover whether lung non-small cell lung cancers fluoresce based on the intraoperative images. The surgeon will look at the images during surgery to determine if the tumor is glowing or not. In the first 10 subjects, if the investigators identify 5 or more subjects with a false positive, then the investigators will review the data prior to proceeding. If the investigators have a high false positive rate, then the investigators will likely not proceed because the clinical value of the fluorescent probe is minimal. Of note, if the first five consecutive subjects have false positives, the investigators will stop the study and analyze the data carefully before proceeding with the study.

Cohort 2: If the first 10 subjects show no significant false positives, then the investigators will continue to examine another 10 subjects.

Eligibility criteria: Inclusion Criteria:

* Adult subjects over 18 years of age
* Subjects presenting with a lung, pleural nodule or mass presumed to be resectable on pre-operative assessment
* Good operative candidate
* Subject is capable of giving informed consent and participating in the process of consent.

Exclusion Criteria:

* At-risk subject populations:

  1. Homeless subjects
  2. Subjects with drug or alcohol dependence
  3. Children and neonates
  4. Subjects unable to participate in the consent process.
* Female patients should not be pregnant or lactating. Women of child-bearing potential will be included provided that they have a negative pregnancy test or provide documentation of sterilization, menopausal or post-menopausal status, prior to infusion.
* Patients who have received SGM-101 in the past.
* Patients who have received any investigational drug four weeks of the injection.

Primary outcomes:
measure: Sensitivity measure of SGM-101 uptake and expression in identifying non-small cell lung cancer
timeFrame: Up to 10 days post surgery (completion of pathology report)
measure: Specificity measure of SGM-101 uptake and expression in identifying non-small cell lung cancer
timeFrame: Up to 10 days post surgery (completion of pathology report)
measure: Number of Adverse Events (AEs) and Treatment-emergent Adverse Events (TEAEs)
timeFrame: Up to 4 weeks post surgery (completion of post-operative follow-up visit)
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Abramson Cancer Center of the University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Sunil Singhal, MD
role: PRINCIPAL_INVESTIGATOR
References: